Abstract 485P
Background
Afatinib is indicated for the treatment of EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC). LUX-Lung trials have demonstrated that afatinib significantly improved progression-free survival (PFS) compared with chemotherapy. We report results from a retrospective study of first-line afatinib in Korean patients with EGFR M+ NSCLC in real-world setting of two hospitals in South Korea.
Methods
Clinical data of Korean patients with stage IV EGFR M+ NSCLC who received first-line afatinib treatment in Pusan National University Yangsan Hospital and Pusan National University Hospital between February 2015 to December 2016 were obtained. Objective response rate (ORR), disease control rate (DCR), PFS, and tolerability were assessed. The treatment response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). PFS was estimated by Kaplan-Meier method and the differences in survival were assessed by log-rank test.
Results
A total of 99 eligible patients were enrolled for analysis. Mean age was 68 years (range: 35-83 years) and 56.6% were female. A total of 96.0% patients were histologically diagnosed with adenocarcinoma with 52.0% brain metastases (BM). ORR was 63.4% and DCR was 93.5%. Intracranial response was 69.6% in patients treated with afatinib plus local therapy and 55.0% with afatinib therapy alone. Median PFS reached 15.1 (95% CI: 12.6-17.4) months in overall, 12.6 (9.9-14.5) months in exon 19 deletion, 16.9 (12.5-21.1) months in exon 21 L858R mutation, 13.1 (1.9 to 22.3) months in rare mutations, 18.6 (14.9-24.2) months in BM absent, and 12.2 (10.9-15.2) months BM present. There is no significantly difference between PFS either by mutation types or by BM status. The most common Grade ≥3 side effects were skin rash/acne (15.2%), and diarrhea (10.1%).
Conclusions
This study indicates that the clinical outcomes achieved with first-line afatinib in Korean patients in real-world setting appear to be better than observed from the LUX-Lung studies. Afatinib can also provide a good intracranial response in patients with brain metastases regardless of whether or not they also receive local treatment.
Clinical trial identification
Editorial acknowledgement
Dr. Luke for the review and helpful comments for this study.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract